Grigoriou O, Papoulias I, Vitoratos N, Papadias C, Konidaris S, Antoniou G, Chryssikopoulos A
2nd Department of Obstetrics and Gynecology, University of Athens, Areteion Hospital, Greece.
Maturitas. 1997 Dec 15;28(2):147-51. doi: 10.1016/s0378-5122(97)00071-6.
The aim of this study was to assess the effects of nasal salmon calcitonin (SCT) administration on bone turnover in ovariectomized women.
Patients who had undergone bilateral ovariectomy 7 days previously, received either calcium supplementation (1000 mg/day, together with nasal SCT (100 IU/day) (n = 19) or the same calcium supplementation together with a placebo intranasal spray daily (n = 19), for 2 years.
In the calcium-only-treated subjects, lumbar bone mineral density (BMD) was found to have decreased significantly (P < 0.001), 6 months after surgery and remained at this level until the end of the study. In the SCT-treated group, BMD remained stable during the 1st year and then decreased gradually, reaching a statistically significant level in the 2nd year. Mean serum osteocalcin concentration was unchanged during the 1st year of SCT treatment but was significantly elevated during the 2nd year (P < 0.01). The observed rise in serum osteocalcin concentration and urinary hydroxyproline excretion during the 2nd year of treatment with SCT was accompanied by a significant rise in serum calcitonin levels (P < 0.001 after 18 months and P < 0.01 after 24 months).
This study shows that continuous treatment with intranasal SCT is able to prevent the bone loss that follows ovariectomy.
本研究旨在评估经鼻给予鲑鱼降钙素（SCT）对去卵巢女性骨转换的影响。
7天前接受双侧卵巢切除术的患者，连续2年每日补充钙剂（1000毫克/天）并经鼻给予SCT（100国际单位/天）（n = 19），或每日补充相同剂量的钙剂并经鼻给予安慰剂喷雾（n = 19）。
仅接受钙剂治疗的受试者，术后6个月腰椎骨密度（BMD）显著下降（P < 0.001），并维持该水平直至研究结束。在SCT治疗组中，BMD在第1年保持稳定，随后逐渐下降，在第2年达到统计学显著水平。SCT治疗第1年血清骨钙素平均浓度未发生变化，但在第2年显著升高（P < 0.01）。SCT治疗第2年观察到血清骨钙素浓度升高和尿羟脯氨酸排泄增加，同时血清降钙素水平显著升高（18个月后P < 0.001，24个月后P < 0.01）。
本研究表明，持续经鼻给予SCT能够预防去卵巢后的骨质流失。
